GlassScriptPhysician profile
Asad Javed
NPI 1598076093
$23,402.55
in general payments reported to CMS, 2019-2025
37 companies · $621 in 2025
The $621 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $262 · 2021: $1,989 · 2022: $5,274 · 2023: $13K · 2024: $1,740 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $3,355 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,000.00 |
| Food and Beverage | $3,354.56 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $18,439.14 | 2021-2023 | Da Vinci Sp, Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $842.32 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $794.44 | 2019-2025 | Nucala, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $299.31 | 2024-2025 | Winrevair, Zerbaxa, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.49 | 2019-2023 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Mallinckrodt Hospital Products INC. | $290.15 | 2021-2023 | Acthar |
| United Therapeutics Corporation | $283.77 | 2021-2025 | Tyvaso, Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $219.38 | 2023-2025 | |
| Amgen INC. | $206.84 | 2024-2025 | Tezspire |
| Mylan Specialty L.P. | $188.98 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $134.30 | 2022-2025 | Prolastin-C Liquid |
| Philips North America LLC | $131.33 | 2019-2024 | (8874) Incourage |
| Actelion Pharmaceuticals US, INC. | $125.31 | 2022-2025 | Opsumit, Uptravi |
| Olympus America INC. | $114.91 | 2019-2020 | |
| Pulmonx Corporation | $114.54 | 2021-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $97.33 | 2019 | |
| Shionogi INC | $72.20 | 2022-2024 | Fetroja |
| Abiomed | $67.93 | 2022 | |
| Insmed, INC. | $65.92 | 2022-2024 | Arikayce |
| Janssen Pharmaceuticals, INC | $61.36 | 2023-2024 | Xarelto |
| Ethicon INC. | $53.77 | 2021 | |
| Genentech, INC. | $53.00 | 2020 | |
| Genzyme Corporation | $50.64 | 2022-2023 | |
| Genentech USA, INC. | $49.25 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $47.14 | 2024 | Purified Cortrophin Gel |
| Pfizer INC. | $41.75 | 2019-2023 | |
| Veran Medical Technologies, INC. | $36.54 | 2020 | |
| Harmony Biosciences LLC | $28.87 | 2023 | Wakix |
| Viatris Specialty LLC | $28.81 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $26.23 | 2024 | |
| Advanced Respiratory, INC | $25.01 | 2019 | |
| Baxter Healthcare | $24.93 | 2023 | Hillrom - Life 2000 Ventilation System |
| Electromed, INC. | $20.35 | 2022 | |
| Paratek Pharmaceuticals, INC. | $20.19 | 2023 | Nuzyra |
| Nabriva Therapeutics, Plc | $19.13 | 2022 | |
| Phadia US INC. | $17.93 | 2024 | Immunocap |
| Mallinckrodt Enterprises LLC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asad Javed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.